Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin E Gore

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
Journal of Hepatology|February 25, 2021
Activation and transcriptional profile of monocytes and CD8<sup>+</sup> T cells are altered in checkpoint inhibitor-related hepatitisCathrin L C Gudd, Lewis Au, Evangelos Triantafyllou, et al.
Lancet (London, England)|November 8, 2011
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trialBrian I Rini, Bernard Escudier, Piotr Tomczak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2011
Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomasDavid S P Tan, Marjan Iravani, W Glenn McCluggage, et al.
Science Translational Medicine|June 3, 2011
A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinomaNatsuko Suwaki, Elsa Vanhecke, Katelyn M Atkins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2009
PPM1D is a potential therapeutic target in ovarian clear cell carcinomasDavid S P Tan, Maryou B K Lambros, Sydonia Rayter, et al.
Cancer Immunology, Immunotherapy : CII|March 11, 2014
Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanomaSander Kelderman, Bianca Heemskerk, Harm van Tinteren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2013
Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional studyJoo Ern Ang, Charlie Gourley, C Bethan Powell, et al.
Nature Medicine|October 7, 2018
Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinomaDavid F McDermott, Mahrukh A Huseni, Michael B Atkins, et al.
Nature Medicine|June 6, 2018
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinomaDavid F McDermott, Mahrukh A Huseni, Michael B Atkins, et al.
JAMA|January 26, 2012
Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancerKelly L Bolton, Georgia Chenevix-Trench, Cindy Goh, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Journal of Hepatology|February 25, 2021
Activation and transcriptional profile of monocytes and CD8<sup>+</sup> T cells are altered in checkpoint inhibitor-related hepatitisCathrin L C Gudd, Lewis Au, Evangelos Triantafyllou, et al.
Lancet (London, England)|November 8, 2011
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trialBrian I Rini, Bernard Escudier, Piotr Tomczak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2011
Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomasDavid S P Tan, Marjan Iravani, W Glenn McCluggage, et al.
Science Translational Medicine|June 3, 2011
A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinomaNatsuko Suwaki, Elsa Vanhecke, Katelyn M Atkins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2009
PPM1D is a potential therapeutic target in ovarian clear cell carcinomasDavid S P Tan, Maryou B K Lambros, Sydonia Rayter, et al.
Cancer Immunology, Immunotherapy : CII|March 11, 2014
Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanomaSander Kelderman, Bianca Heemskerk, Harm van Tinteren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2013
Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional studyJoo Ern Ang, Charlie Gourley, C Bethan Powell, et al.
Nature Medicine|October 7, 2018
Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinomaDavid F McDermott, Mahrukh A Huseni, Michael B Atkins, et al.
Nature Medicine|June 6, 2018
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinomaDavid F McDermott, Mahrukh A Huseni, Michael B Atkins, et al.
JAMA|January 26, 2012
Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancerKelly L Bolton, Georgia Chenevix-Trench, Cindy Goh, et al.
Pageof 6